Overview
Eascra Biotech is an early-stage nanomedicine startup based in Massachusetts. Our proprietary technology is a Janus Base nanoparticle (JBNp), an alternative to the lipid nanoparticles (LNPs), whose structural design is inspired by DNA. We help pharmaceutical, biotech, gene editing, and other therapeutic partners precision deliver their payloads to hard-to-penetrate treatment sites like articular cartilage, kidneys, brain cells, liver, and other organs. Our JBNps can also penetrate ECM-rich solid tumors, e.g., ovarian cancer tumors. Our delivery platform can accommodate a variety of cargoes of various sizes including different types of RNA, proteins, small molecule drugs, gene editing materials, etc.
Our JBNps bind tightly with a cargo rendering it room temperature stable for extended bioactivity. JBNp’s unique rod shape and slimmer design allows for easy penetration of the cell wall via endocytosis. It’s DNA-like structure does not trigger immunogenicity so we can deliver a full therapeutic cargo that will retain bioactivity longer for better treatment outcomes with less dosing. Unlike LNPs, our JBNps are manufactured in a simple self-assembly process. JBNps are easy to load, maintain bioactivity at ambient temperature for an extended period of time and are less toxic (minimal liver accumulation).
Eascra Biotech is part of an elite groups of life science companies currently working with NASA, the ISS National Lab, the NSF, and a private space company, Axiom Space, to utilize low gravity orbit for accelerated product development. We are actively seeking life science partners and visionary private investors interested in our new, versatile therapeutic delivery solution that can provide a more functionally capable alternative for better patient outcomes with less side effects.
Contact our CEO, Mari Anne Snow at masnow@eascrabiotech.com for more details.
Company News
